Managed Healthcare Executive April 16, 2024
Factors preventing biosimilar access include pharmacy benefit manager contracts and pharmacies not communicating with providers, a survey finds.
Despite the introduction of biosimilars, brand-name reference products still have the highest market share across the eight therapeutic areas, according to the survey data presented in a poster at the Academy of Managed Care Pharmacy (AMCP) annual meeting in New Orleans.
The survey was conducted by a team from Precision Value and Health, a healthcare consulting firm. Data was based on an October 2023 survey of 25 people from health plan stakeholders. The eight therapeutic areas are rare disease, multiple sclerosis, pulmonary, ophthalmology, inflammatory/autoimmune disorders, diabetes, oncology and oncolytic therapy. According to the poster, the market with the largest number of reference...
Today's Sponsors
Today's Sponsor